Clinical Observation of Entecavir Combined with Long-acting Interferon in the Treatment of HBeAg Positive Chronic Hepatitis B / 中国药房

OBJECTIVE:To observe therapeutic efficacy and safety of entecavir combined with long-acting interferon in the treatment of HBeAg positive chronic hepatitis B (CHB).METHODS:A total of 140 patients with HBeAg positive CHB selected from our hospital during May 2013-May 2015 were divided into observation group and control group according to random number table,with 70 cases in each group.Both groups received routine liver-protecting treatment;control group was additionally given Peginterferon α-2b injection 80 μg subcutaneously,once a week;observation group was additionally given Entecavir dispersible tablets 0.5 mg,po,qd,on the basis of control group.Both groups received treatment for consecutive 50 weeks.Clinical efficacies,liver function indexes before and after treatment,virological efficacies and the occurrence of ADR of 2 groups were observed.RESULTS:Each 5 cases withdrew from the study in 2 groups,and 130 cases (65 cases in each group) completed the study.Total response rate of observation group was 90.8％,which was significantly higher than 76.9％ of control group,with statistical significance (P＜0.05).Before treatment,there was no statistical significance in the levels of ALT,AST,ALB or TBIL between 2 groups (P＞0.05).After treatment,the levels of ALT,AST and TBIL in 2 groups were decreased significantly,while ALB level was increased significantly,the observation group was significantly better than the control group,with statistical significance (P＜0.05).After 50 weeks of treatment,the negative conversion rate of HBV-DNA,HBeAg serology conversion rate and ALT normalizing rate of observation group were significantly higher than those of control group,and virologic breakthrough rate was significantly lower than control group,with statistical significance (P＜0.05).No severe ADR was found in 2 groups.There was no statistical significance in the incidence of ADR (P＞0.05).CONCLUSIONS:The entecavir combined with long-acting interferon show defmite therapeutic efficacy for HBeAg positive CHB,inhibit the replication of HBV and improve liver function of patients with good safety.

Observation on the effect of long-acting interferon injection and nucleoside drugs on serum interleukin 37 levels and clinical effect in patients with hepatitis B / 中国生化药物杂志

Objective To investigate the effect of long-acting interferon injection and nucleoside drugs on serum interleukin 37 levels and clinical effect in patients with hepatitis B.Methods 172 patients with Chronic hepatitis B from the Department of liver disease in our hospital were selected and divided into 2 groups, 86 cases in the control group treated with Entecavir, 86 cases in the experiment group received Polyethylene glycol interferon α-2a treatment on the basis of the control group, serum levels of inflammatory factors, peripheral blood T lymphocyte level, serum level of hepatic fibrosis index, and the clinical effect were compared after the treatment.Results The effective rate in the control group(63.95%)was lower than the experiment group(81.40%), with significant difference (P<0.05), the DNA HBV negative conversion rate, HBeAg negative conversion rate, HBeAg conversion rate and ALT recovery rate in control group after treatment were lower than the experiment group, with significant difference (P<0.05), compared with the control group, serum levels of IL-37、IL-6、IL-18、IL-12 were lower after treatment in the experiment group, peripheral blood levels of CD4 + T lymphocyte and CD4 +/CD8 +ratio were higher, and peripheral blood levels of CD8 +T lymphocyte weaas lower after treatment, serum levels of HA、PCⅢ、Ⅳ-C and LN were lower after treatment, with significant difference (P<0.05).Conclusion Long-acting interferon injection and nucleoside drugs can significantly reduce the serum levels of IL-37, IL-6, IL-18, IL-12 in patients with hepatitis B, reduce the inflammatory reaction, improve the cellular immune function, inhibit liver fibrosis, the clinical effect was good.

Research progress of the anti-hepatitis virus mechanism of interferon-alpha and long-acting form of interferons / 中国药理学通报

Interferon-alpha is one of the most important drugs against hepatitis virus,and it can inhibit the replication of virus by inducing the expression of 2'-5'-OAS,PKR,MxA through Jak-STAT pathway in hepatocytes.The effects are also concerned with other signal pathways,such as MAPK,IRS-1/PI3K-p70S6 kinase pathways and so on.In order to prolong the half life of interferon-alpha and enhance its effectiveness,many other long-lasting interferons are developed,such as pegylated interferon,recombinant human serum albumin-interferon,and liposome interferon,which maybe take the place of interferon-alpha.The research and development of more long-acting and efficient interferons are becoming a more and more important way to the anti-virus treatment of hepatitis.